This prospective, multicentric, phase 4 study enrolled 747 T2D patients uncontrolled (A1c≥7) on Metformin+SU combination to receive add on HCQ 400 mg/day for 52 weeks. Primary outcome measure was, long term safety of HCQ evaluated in ITT population (n=747). Secondary outcomes were post treatment changes in glycemic, lipids and inflammatory parameters. Total of 191 AEs were reported in 111 patients, most were GI related (26.2%), mild in intensity (85%) and unlikely related (70%) to HCQ. Level 1 hypoglycemia was reported in 6.8% patients and mild NPDR in 11 patients. Of the 9 SAEs reported, 8 were unrelated and 1 (anemia) was probably related to HCQ. In mITTc population, the overall fall in A1c, FBG and PPG at week 12, 24 and 52 was significant from baseline. Additionally, a significant fall in TC, LDL-C, non-HDL-C was reported at week 24 and 52 from baseline. Patients were divided in two subgroups based on their baseline hsCRP levels (≤3 or ≥3). Of the 52% females enrolled, more than 60 % had high inflammatory load at baseline. There was significant fall in A1c, FBG, PPG, LDL-C, TC, and non-HDL-C at week 24 and 52 irrespective of baseline hsCRP. However, fall in A1C was significantly more at week 12 and 24 in patients with higher inflammatory load (hsCRP: ≥3) at baseline (p<0.0001). T2D is characterized by chronic low grade inflammation (meta-inflammation). HCQ has significantly reduced glycemic parameters with added benefits on lipids

Disclosure

A.Pareek: None. N.Chandurkar: None. K.B.Naidu: None. P.Dicholkar: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.